Jci_page_head_homepage_01 Jci_page_head_homepage_02
Shawn M. Sumida, Paul F. McKay, Diana M. Truitt, Michael G. Kishko, Janelle C. Arthur, Michael S. Seaman, Shawn S. Jackson, Darci A. Gorgone, Michelle A. Lifton, Norman L. Letvin, Dan H. Barouch
Published in Volume 114, Issue 9
J Clin Invest. 2004; 114(9):1334–1342 doi:10.1172/JCI22608
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 8

Recombinant vaccinia virus challenge. BALB/c mice (n = 4 per group) were immunized intramuscularly with sham plasmid, gp120 DNA vaccine, or gp120 DNA vaccine with plasmid Flt3L and plasmid MIP-1α. At week 12 following immunization, mice were challenged i.p. with 107 PFU recombinant vaccinia virus expressing HIV-1 env IIIB. (A) Anamnestic immune responses were assessed by Dd/P18 tetramer binding to CD8+ T lymphocytes following challenge. (B) Vaccinia virus titers (PFU) were assessed in ovaries harvested on day 7 following challenge.